Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | ESR1 | P03372 | 7/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401576 | 1.00 | ESR2 (0.41) | ESR2ESR1PDK2NR3C1TACR1 | |
| SCHEMBL6402105 | 1.00 | ESR2 (0.41) | ESR2ESR1PDK2NR3C1TACR1 | |
| SCHEMBL6400509 | 0.79 | PDK2 (0.43) | ESR2ESR1PDK2TACR1DRD2 | |
| SCHEMBL6406622 | 0.79 | PDK2 (0.43) | ESR2ESR1PDK2TACR1DRD2 | |
| SCHEMBL6400531 | 0.79 | PDK2 (0.43) | ESR2ESR1PDK2TACR1DRD2 | |
| SCHEMBL15775016 | 0.79 | ESR2 (0.46) | ESR2ESR1NR3C1DRD2DRD1 | |
| SCHEMBL6401257 | 0.78 | CA2 (0.42) | ESR1TACR1OPRM1ALDH1A1LMNA | |
| SCHEMBL6401391 | 0.78 | CA2 (0.42) | ESR1TACR1OPRM1ALDH1A1LMNA | |
| SCHEMBL14158496 | 0.76 | OPRM1 (0.40) | ESR2ESR1PDK2TACR1OPRM1 | |
| SCHEMBL11224537 | 0.69 | ESR2 (0.41) | ESR2ESR1NR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1178984-B1 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | PFIZER PROD INC (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1178984-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071538-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | ESR2 674/4885ESR1 497/4885PDK2 3515/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | ESR2 720/4885ESR1 989/4885PDK2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.